🚀 VC round data is live in beta, check it out!
Apogee Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Apogee Therapeutics and similar public comparables like Glenmark Pharma, Protagonist Therapeutics, Arcellx, Bachem and more.
Apogee Therapeutics Overview
About Apogee Therapeutics
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Founded
2023
HQ
Employees
196
Website
Sectors
Financials (LTM)
EV
$6B
Apogee Therapeutics Financials
Apogee Therapeutics reported last 12-month revenue of — and negative EBITDA of ($306M).
In the same LTM period, Apogee Therapeutics generated — in gross profit, ($306M) in EBITDA losses, and had net loss of ($276M).
Revenue (LTM)
Apogee Therapeutics P&L
In the most recent fiscal year, Apogee Therapeutics reported revenue of — and EBITDA of ($284M).
Apogee Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($306M) | XXX | ($284M) | XXX | XXX | XXX |
| Net Profit | ($276M) | XXX | ($256M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Apogee Therapeutics Stock Performance
Apogee Therapeutics has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Apogee Therapeutics' stock price is $92.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | 1.8% | XXX | XXX | XXX | $-3.43 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialApogee Therapeutics Valuation Multiples
Apogee Therapeutics trades at (20.1x) EV/EBITDA.
Apogee Therapeutics Financial Valuation Multiples
As of April 18, 2026, Apogee Therapeutics has market cap of $7B and EV of $6B.
Equity research analysts estimate Apogee Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Apogee Therapeutics has a P/E ratio of (24.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/EBITDA | (20.1x) | XXX | (21.7x) | XXX | XXX | XXX |
| EV/EBIT | (20.3x) | XXX | (21.6x) | XXX | XXX | XXX |
| P/E | (24.9x) | XXX | (26.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (26.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Apogee Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Apogee Therapeutics Margins & Growth Rates
Apogee Therapeutics' revenue in the last fiscal year grew by —.
Apogee Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.
Apogee Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 22% | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Apogee Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Apogee Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Glenmark Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Protagonist Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcellx | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| China Resources Sanjiu | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apogee Therapeutics M&A Activity
Apogee Therapeutics acquired XXX companies to date.
Last acquisition by Apogee Therapeutics was on XXXXXXXX, XXXXX. Apogee Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Apogee Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialApogee Therapeutics Investment Activity
Apogee Therapeutics invested in XXX companies to date.
Apogee Therapeutics made its latest investment on XXXXXXXX, XXXXX. Apogee Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Apogee Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Apogee Therapeutics
| When was Apogee Therapeutics founded? | Apogee Therapeutics was founded in 2023. |
| Where is Apogee Therapeutics headquartered? | Apogee Therapeutics is headquartered in United States. |
| How many employees does Apogee Therapeutics have? | As of today, Apogee Therapeutics has over 196 employees. |
| Who is the CEO of Apogee Therapeutics? | Apogee Therapeutics' CEO is Michael Henderson. |
| Is Apogee Therapeutics publicly listed? | Yes, Apogee Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Apogee Therapeutics? | Apogee Therapeutics trades under APGE ticker. |
| When did Apogee Therapeutics go public? | Apogee Therapeutics went public in 2023. |
| Who are competitors of Apogee Therapeutics? | Apogee Therapeutics main competitors are Glenmark Pharma, Protagonist Therapeutics, Arcellx, Bachem. |
| What is the current market cap of Apogee Therapeutics? | Apogee Therapeutics' current market cap is $7B. |
| Is Apogee Therapeutics profitable? | No, Apogee Therapeutics is not profitable. |
| What is the current EBITDA of Apogee Therapeutics? | Apogee Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Apogee Therapeutics? | Current EBITDA multiple of Apogee Therapeutics is (20.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.